RCM
ATRS

Rotella Capital Management’s Antares Pharma, Inc. ATRS Stock Holding History

Rotella Capital Management’s Portfolio ATRS Stock Details ATRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-34,103
Closed -$71K – 692
2015
Q2 		$71K Buy
+34,103
New +$82.7K 0.06% 330

Other funds holding ATRS

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
WHI
William Harris Investors Chicago, Illinois $347M AUM 3.53% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Rotella Capital Management's ATRS Position: Q3 2015 in Review

Rotella Capital Management sold out of Antares Pharma, Inc. (ATRS) in Q3 2015, closing a stake of 34,103 shares — an estimated $71K sold.

Rotella Capital Management first reported a position in ATRS in Q2 2015 and held it in 1 quarter. The position peaked at $71K in Q2 2015. 90 funds tracked by Wall St. Rank hold ATRS as of Q3 2015.

  • Rotella Capital Management reported no remaining Antares Pharma, Inc. position as of Q3 2015 after selling out during the quarter.
  • Rotella Capital Management sold 34,103 Antares Pharma, Inc. shares in Q3 2015, an estimated $71K.
  • Rotella Capital Management first reported a position in Antares Pharma, Inc. in Q2 2015 and held it in 1 quarter.
  • Rotella Capital Management's Antares Pharma, Inc. position peaked at $71K in Q2 2015.
  • 90 funds tracked by Wall St. Rank held Antares Pharma, Inc. as of Q3 2015.

Based on Rotella Capital Management's 13F filing for Q3 2015, filed 13 Nov 2015.